Title	Address	Description
LMU	GESCHWISTER SCHOLL PLATZ 1, 80539 München,
Fundació Clínic per a la Recerca Biomèdica	Carrer del Rosselló, 149, 08036 Barcelona, Spanien
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)	Ingolstädter Landstraße 1, 85764 Oberschleißheim, Deutschland
Helmholtz Munich	Inhoffenstraße 7, 38124 Braunschweig, Deutschland
Medizinische Hochschule Hannover	Carl-Neuberg-Straße 1, 30625 Hannover, Deutschland
NIMR-Mbeya Medizinisches Forschungszentrum	Hospital Hill Rd, Mbeya, Tansania
Technische Universität München	Arcisstraße 21, 80333 München, Deutschland
UNIVERSITY COLLEGE LONDON (UCL)	GOWER STREET, WC1E 6BT London
Klinikum Rechts der Isar der Technischen Universität München	Hörsaal A, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 München, Deutschland
UKE Hamburg Eppendorf	Martinistraße 52, 20251 Hamburg, Deutschland
Azienda Ospedaliero- Universitaria di Parma	Str. dell'Università, 12, 43121 Parma PR, Italien
Universitätsklinikum Leipzig	Ritterstraße 26, 04109 Leipzig, Deutschland
Barts Health NHS Trust	Co-operative Bank Plc, 9 Prescot St, Whitechapel, London E1 8AZ, Vereinigtes Königreich
Royal Free London NHS Foundation Trust	Pond St, Hampstead, London NW3 2QG, Vereinigtes Königreich
PNO Innovation GmbH	Oskar-von-Miller-Ring 29, 80333 München, Germany
SocraTec R&D GmbH	Im Setzling 35, 61440 Oberursel (Taunus), Deutschland
Universitätsklinikum Frankfurt	Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Deutschland

Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)

General Information

The Helmholtz Centre for Infection Research (HZI) in Braunschweig is a publicly funded research centre with more than 900 employees and an annual budget of approximately 70 million Euros as well as external funds of approximately 16 million Euros from national and international support programmes and industry. The focus of its activities lies in the field of infection. The mission of the HZI is to rise to the societal challenges of infectious diseases by investigating their fundamental mechanisms of pathogenesis, with the aim of deriving innovative approaches for their prevention, diagnosis and therapy. The HZI is also a member of the German Centre for Infection Research (35 research institutions located at seven sites), with the managing office located at the HZI campus.

The scientific activities in the Department of Vaccinology and Applied Microbiology, headed by Prof. Carlos A. Guzmán are dedicated to:

elucidating the mechanisms of host response to infection and vaccination,
developing new adjuvants and antigen delivery systems, and
developing and validating vaccines against specific infectious diseases.

This encompasses:

establishing adjuvants and nanocarrier-based delivery systems,

developing vaccines against specific pathogens (eg. hepatitis B and C viruses, influenza virus, Trypanosoma cruzi),
generating advanced immune monitoring approaches to assess innate and adaptive immune responses following vaccination in preclinical models and humans,
assessing responses to vaccines in humans, and
identifying genotypic and early phenotypic immune signatures predicting successful vaccination.

Helmholtz-Zentrum für Infektionsforschung GmbH

Inhoffenstr. 7
38124 Braunschweig
Germany

www.helmholtz-hzi.de/en

Role in TherVacB

Prof. Guzmán and his group at the HZI have studied and developed c-di-AMP as a potent novel adjuvant and patented its use for therapeutic and prophylactic vaccination. Non-GLP proof-of-principle studies demonstrated that c-di-AMP was able to improve both the humoral and the cellular immune responses to disease-related antigens of Streptococcus pyogenes, HBV, HCV, influenza virus, and Trypanosoma cruzi upon parenteral or mucosal vaccination. The HZI will not only contribute c-di-AMP to the TherVacB project, it will also contribute its expertise to assist in preparing the clinical trial dossiers, obtaining regulatory approval and developing the data management plan, as well as support data collection and management during the clinical trial.